[{"orgOrder":0,"company":"PPD","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RQ-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Theratechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Ioflupane","moa":"Dopamine transporter (DAT)","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Liquidia Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"PPD","sponsor":"Altavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Dizal Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR Exon20ins mutant (EGFR Exon20ins)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"PPD","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Versameb","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, mRNA","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CYP450","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ US Army","highestDevelopmentStatusID":"1","companyTruncated":"PPD \/ US Army"}]
Find Clinical Drug Pipeline Developments & Deals by PPD
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target